The ipamorelin clinical trial most often cited did not meet its main goal. It tested whether hospitalized adults could eat sooner after bowel surgery. The median was 25.3 hours with ipamorelin and 32.6 hours with placebo, an inactive comparison. The difference was not statistically significant. This was a short gut-recovery study, not evidence for muscle gain, better sleep, or long-term use.
What question did the ipamorelin clinical trial ask?
Could ipamorelin shorten postoperative ileus, the temporary slowdown of the gut after surgery? That was the question behind the Ipamorelin 201 study, published by Beck and colleagues in International Journal of Colorectal Disease in 2014.
Ipamorelin activates the ghrelin receptor, a cell switch normally used by a hormone involved in hunger and gut movement. Researchers hoped that activating it would help the bowel start moving again.
The idea had animal evidence behind it. Venkova and colleagues, in JPET in 2009, found changes in bowel recovery in operated rats. Greenwood-Van Meerveld and colleagues, in Journal of Experimental Pharmacology in 2012, reported faster stomach emptying in another rat experiment. Those findings justified testing the idea in people; they did not settle the answer.
The ipamorelin benefits guide covers other studied uses.
Who was enrolled, and for how long?
The Beck 2014 paper's abstract reports 117 enrolled adults, with 114 included in the safety and main treatment analyses. They underwent small- or large-bowel resection, surgery removing part of the intestine. Procedures included open surgery and surgery through small incisions.
The study assigned treatment by chance. It was double-blind, meaning participants and investigators did not know who received ipamorelin or placebo.
Eligibility allowed adults ages 18–85. The registry excluded pregnancy, clinical instability, significant liver disease, and important laboratory or heart-tracing abnormalities. The study did not represent every person recovering from surgery.
The trial used 0.03 mg/kg ipamorelin by intravenous infusion, delivery into a vein, twice daily. Treatment began the day after surgery and lasted until day seven or hospital discharge, whichever came first. That describes the hospital experiment. The prescriber sets any actual dose.
As of October 1, 2026, the day this article was written, NCT00672074 lists Helsinn Therapeutics (U.S.), Inc. as sponsor, 117 participants, and completed status. Its last posted update is April 14, 2017; no registry results are posted. The journal publication supplies the findings.
The study tested ipamorelin alone. It cannot establish results for a tesamorelin/ipamorelin combination simply because that combination includes the same molecule.
What was measured, and what happened?
25.3 hours versus 32.6 hours was the headline result. These were medians, the middle values, for time from the first study dose to tolerating a standardized solid meal.
The meal test assessed eating without the nausea or vomiting that would count as failure. It measured recovery of eating, rather than a growth-hormone level or a change in body fat.
The reported P value was 0.15. A P value describes how compatible the data are with chance variation if there is no treatment difference. The authors reported that this result was not statistically significant. The shorter time therefore did not establish a treatment benefit.
Other measures included the first bowel movement, recovery of both eating and bowel movements, readiness for discharge, and hospital stay. The paper reported no significant differences in its secondary efficacy analyses, the additional tests of whether treatment helped.
The trial did not demonstrate the benefit it set out to test.
What did the side-effect results show?
Nearly nine in ten ipamorelin participants had an adverse event, an unwanted medical event recorded after treatment began. Such an event is not automatically caused by the medicine.
| Safety measure reported in the published abstract | Ipamorelin | Placebo |
|---|---|---|
| Any event beginning or worsening during treatment | 87.5% | 94.8% |
These rates came from people recovering from bowel surgery. They cannot be used as outpatient side-effect rates.
The FDA's briefing for its October 29, 2024 advisory meeting gives more detail. Common events included nausea, vomiting, and abdominal swelling. It also identified low potassium and high blood sugar more often with ipamorelin. Serious events, including deaths, occurred; their relationship to ipamorelin was unclear.
The authors described the short course as “well tolerated.” That phrase needs the setting attached to it. It does not mean nobody had a serious event or that months of treatment were assessed.
The ipamorelin side-effects guide covers the wider safety questions. For CJC-1295/ipamorelin, adding another molecule also means this single-compound trial cannot establish the blend's safety.
What later evidence adds
The authors acknowledged a small study with varied underlying conditions. FDA's later review also described a more favorable signal in people having open surgery. A subgroup, one smaller slice of the study population, cannot replace an unsuccessful overall result.
A second surgical study matters too. As of October 1, 2026, the day this article was written, NCT01280344 lists 320 participants and completed status, with no posted results. A completed registry record is not evidence of a successful result.
Other human reports are different kinds of evidence. As of October 1, 2026, the day this article was written, a 2026 ovarian-function case series describes four women receiving ipamorelin alongside other interventions. It had no comparison group and cannot isolate ipamorelin's contribution. It does not establish a general wellness benefit.
As of October 1, 2026, the day this article was written, Tewari and colleagues' review, published August 11, 2026 in The American Journal of Sports Medicine, found no clinical evidence for ipamorelin in musculoskeletal injury or performance. That means recovery of muscles, bones, and related tissues. The review maps existing studies; it is not a new treatment trial.
Why “tested in humans” gets overread
A common retelling combines two facts: ipamorelin reached phase 2, an early test of treatment benefit, and researchers called it well tolerated. It then treats them as support for sleep, muscle, or fat-loss claims. Those outcomes were not tested here.
The selectivity claim comes from a different source. Raun and colleagues' 1998 paper in European Journal of Endocrinology studied cells, rats, and pigs. Ipamorelin prompted growth-hormone release without the same stress-hormone response seen with older compounds. These were animal findings.
The CJC-1295/ipamorelin evidence guide explains the separate component studies. Neither a hormone response nor this hospital trial proves a result for the combination.
What this means for a compounded prescription
As of October 1, 2026, the day this article was written, an FDA letter dated August 24, 2026 addressed online claims for a tesamorelin/ipamorelin blend among other products. FDA treated the seller's products as unapproved drugs despite laboratory-use labeling. That action concerns those products and claims, not a new clinical-trial result.
A prescribed route provides a named clinician, a licensed U.S. dispensing pharmacy, documented medication and lot information, and a path for reporting reactions. The evidence gaps remain.
Ipamorelin is not FDA-approved. Compounded medications, prepared by a pharmacy for an individual prescription, are different from an FDA-approved product: the compounded formulations are not FDA-approved. A licensed provider may still prescribe — that decision is between you and your doctor. The ipamorelin FDA review history covers the regulatory record.
For CJC-1295/ipamorelin, the useful discussion concerns the actual formulation and treatment goal. A study of short hospital infusions cannot establish how a compounded combination behaves during longer use.
A visit needs a question the trial can answer
The practical questions are what outcome is being sought, which evidence matches it, and how benefit and unwanted effects will be assessed. Eating after surgery is a measured outcome. Better sleep or more muscle requires different evidence.
At Promise, a licensed provider reviews every request and not everyone qualifies. If treatment is prescribed, that provider sets the dose and follow-up plan. The trial informs that conversation without supplying a protocol.
